International Stem Cell CORP (ISCO)
International Stem Cell Corp. (ISCO) develops cell and regenerative therapies in a regulatory environment defined by FDA oversight of cell-based products, evolving agency guidance on manufacturing and efficacy standards, and the scientific and legal constraints governing stem-cell research and commercialization.
The Regulatory Ambiguity of Cell Therapies
ISCO operates in a regulatory domain where the FDA is still establishing clear pathways. Cell therapies—products composed of living human cells—are novel. The FDA considers them drugs, biologics, or combination products depending on how they are manufactured and used. This classification determines which FDA center has jurisdiction, what approval pathway applies, and what manufacturing standards the company must satisfy. ISCO must work with the FDA to determine the regulatory classification of each product candidate, and the FDA’s classification can change as scientific understanding evolves or as agency guidance is updated.
The regulatory ambiguity extends to the very starting material. Stem cells sourced from embryos, adult tissues, or induced pluripotent stem cells (iPSCs) derived from reprogrammed adult cells raise distinct regulatory and ethical questions. The FDA’s position on embryonic stem cells has shifted with political administrations. Research using human embryonic stem cells is subject to federal funding restrictions (Dickey-Wirth Amendment limitations) that do not apply to iPSC research. ISCO must navigate not just FDA rules, but also federal restrictions on research funding and state-level restrictions (some states prohibit embryonic stem-cell research, others fund it) that shape where the company can conduct research and how it can access capital.
The 351(k) Pathway and Biosimilar-Like Requirements
For cell therapies derived from human cells, the FDA has proposed applying an approval pathway analogous to the Biosimilar pathway (351(k) under the Public Health Service Act). This pathway is not fully established, and guidance is still evolving. ISCO must conduct clinical trials that demonstrate safety and efficacy, but the FDA’s standards for what constitutes adequate evidence for a cell therapy product are less formulaic than for chemical drugs. The agency requires preclinical characterization of the cells, demonstration of potency (a measure of the product’s biological activity), and identification of critical quality attributes that affect safety and efficacy. The exact standards the FDA will apply to ISCO’s candidates remain somewhat uncertain, creating regulatory risk around trial design, approval timelines, and what clinical data will be sufficient.
Manufacturing Controls and Characterization Requirements
Cell therapies are sensitive to manufacturing variations. The FDA requires ISCO to establish tight manufacturing controls, characterization of the cell population, sterility and potency testing, and stability studies demonstrating that the product maintains its characteristics over its shelf life. Cell-based products are often less stable than chemical drugs; they may require special handling, refrigeration, or rapid use. The manufacturing controls must account for batch-to-batch variability inherent in biological manufacturing. This is far more complex than manufacturing a chemical drug, and regulatory requirements are stricter.
ISCO must validate its manufacturing process and demonstrate that the process is consistent and repeatable. Any process changes require regulatory notification and, for major changes, potentially new clinical data. This locks ISCO into its manufacturing approach once it has demonstrated the approach to the FDA. Scaling up manufacturing or moving production to a new facility triggers regulatory review and potentially requires additional validation studies.
Potency Assays and the Absence of Standard Assays
A critical regulatory requirement is demonstration of potency—the biological activity of the product. For cell therapies, there are rarely standardized potency assays. ISCO must develop its own assays and validate them to FDA standards. A potency assay must be repeatable, reproducible, and predictive of clinical efficacy. If the assay is not scientifically sound, the FDA will reject it, and the company must redesign it. This adds time and expense to development and leaves ISCO exposed to regulatory setback if the agency questions the assay’s validity.
Clinical Trial Design and Endpoint Selection
Because cell therapies are novel, designing clinical trials that satisfy FDA expectations for efficacy is itself a regulatory challenge. ISCO must propose trial designs (through an IND application) that adequately test efficacy. For some indications, traditional randomized controlled trials may be impractical (e.g., for severe degenerative diseases where no alternative therapy exists). ISCO may need to propose non-traditional trial designs, adaptive designs, or even single-arm studies. The FDA must agree that the trial design is adequate to characterize the product’s efficacy. If the FDA and ISCO disagree about trial design, it can delay clinical development substantially.
Endpoint selection is also regulated. The FDA approves the primary endpoint—the measure by which efficacy will be judged. For regenerative therapies, endpoints may be subjective (e.g., patient-reported pain or function) or require biomarkers that are not yet established. ISCO must work with the FDA to define endpoints that are meaningful to patients and regulators and that are measurable within the trial timeline.
Cell Source and Immunogenicity
Depending on the cells ISCO uses, immunogenicity (the risk that the patient’s immune system will attack the transplanted cells) is a regulatory concern. Allogeneic cells (from a donor) are more immunogenic than autologous cells (from the patient), but autologous approaches are more complex and expensive. ISCO must conduct immunogenicity studies and manage the regulatory expectations around immune rejection. Allogeneic approaches may require systemic immunosuppression, which introduces additional safety risks that the FDA will scrutinize.
Right-to-Try and Compassionate Use Exceptions
The FDA permits patient access to investigational cell therapies outside clinical trials in limited circumstances: under Expanded Access (compassionate use) programs or under Right-to-Try state laws. ISCO can make cell therapies available to terminally ill patients who have exhausted standard treatments. However, this access is regulated, and the company must monitor and report safety data to the FDA. Adverse events in compassionate-use patients can trigger FDA inquiries and potential restrictions on the broader clinical program.
Manufacturing Scale and GMP Readiness
Cell therapies require manufacturing under Current Good Manufacturing Practice (CGMP). ISCO must establish manufacturing operations that meet CGMP standards, which demand environmental controls, personnel training, quality-control processes, and validation studies. GMP manufacturing is far more expensive than research-phase manufacturing. ISCO must be prepared to transition from research-scale production to GMP-certified production before advancing to large Phase 3 trials. The cost and timeline of achieving GMP readiness is a material gate in the company’s development schedule.
International Regulatory Variation
ISCO likely seeks to commercialize products not just in the U.S., but in Europe, Japan, and other markets. Each market has distinct regulatory frameworks for cell therapies. The European Medicines Agency (EMA) has established a more defined pathway for Advanced Therapy Medicinal Products (ATMPs), which includes cell therapies. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has created conditional approval pathways for regenerative medicines, with expedited timelines but greater post-market data collection requirements. ISCO’s development timelines and costs are affected by its strategy to pursue parallel global regulatory programs versus staged geographic entry.
Intellectual Property and Trade Secrets in Cell Banks
ISCO’s manufacturing depends on cell banks—frozen stores of cells at a specific passage number from which batches are derived. The identity and characterization of the cell bank is regulatory-critical and must be disclosed to the FDA. However, the cell source, donor information, and manufacturing derivation of the cell bank may be proprietary. ISCO must disclose sufficient information to the FDA for approval while protecting trade secrets. The balance between regulatory transparency and proprietary protection is delicate.
Contamination Risk and Lot Release
Each manufacturing batch of ISCO’s cell therapy must pass sterility and microbial-contamination testing before release. Cell-culture environments are vulnerable to bacterial, fungal, and viral contamination. If a batch fails testing, it is rejected and the patient dose is lost. For allogeneic cell therapies, lost batches can delay patient treatment. For autologous therapies (cells derived from the patient), a failed batch may mean the patient cannot receive treatment. Regulatory requirements around batch testing and lot release create operational and commercial risk.
Evolving FDA Guidance and Retroactive Compliance
The FDA is actively developing guidance documents for cell and gene therapies. As new guidance is issued, ISCO may find that previously acceptable manufacturing or trial designs no longer align with the agency’s current expectations. ISCO must monitor FDA guidance, engage with the agency through pre-submission meetings, and be prepared to adapt its regulatory strategy. Guidance changes can retroactively affect ongoing trials or manufacturing operations, requiring costly modifications.
Long-Term Safety and Durability Data
Cell therapies often aim to provide durable effects—the transplanted cells persist and provide therapeutic benefit over years or decades. The FDA requires long-term safety and efficacy data. ISCO must commit to following patients for extended periods (5, 10, or 20+ years) and collecting data on durability, any delayed adverse effects, and tumorigenic risk (the theoretical risk that transplanted cells could become malignant). This long-term commitment is costly and extends the timeline to demonstrating commercial viability.